Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Identification and metabolic profiling of a novel human gut-derived LEAP2 fragment

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Dynamic changes of reproductive hormones in male minipuberty: Temporal dissociation of Leydig- and Sertoli-cell activity

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Severe mental illness and the risk of diabetes complications. A nationwide register-based cohort study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Patients with cirrhosis have elevated bone turnover but normal hepatic production of osteoprotegerin

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Lipoprotein(a) levels at birth and in early childhood: The COMPARE Study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Colonic lactulose fermentation has no impact on glucagon-like peptide-1 and peptide-YY secretion in healthy young men

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Beta-hydroxybutyrate suppresses hepatic production of the ghrelin receptor antagonist, LEAP2

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Drug use in patients with short bowel syndrome and intestinal failure

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. THERAPY OF ENDOCRINE DISEASE: Amylin and calcitonin - physiology and pharmacology

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  4. LEAP2 reduces postprandial glucose excursions and ad libitum food intake in healthy men

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Long-acting amylin analogues for the management of obesity

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

Vis graf over relationer

CONTEXT: The mechanisms underlying Roux-en-Y gastric bypass (RYGB) surgery-induced weight loss and the immediate postoperative beneficial metabolic effects associated with the operation remain uncertain. Enteroendocrine cell (EEC) secretory function has been proposed as a key factor in the marked metabolic benefits from RYGB surgery. OBJECTIVE: To identify novel gut-derived peptides with therapeutic potential in obesity and/or diabetes by profiling EEC-specific molecular changes in obese patients following RYGB-induced weight loss. SUBJECTS AND METHODS: Genome-wide expression analysis was performed in isolated human small intestinal EECs obtained from 20 gut-biopsied obese subjects before and after RYGB. Targets of interest were profiled for preclinical and clinical metabolic effects. RESULTS: Roux-en-Y gastric bypass consistently increased expression levels of the inverse ghrelin receptor agonist, liver-expressed antimicrobial peptide 2 (LEAP2). A secreted endogenous LEAP2 fragment (LEAP238-47) demonstrated robust insulinotropic properties, stimulating insulin release in human pancreatic islets comparable to the gut hormone glucagon-like peptide-1. LEAP238-47 showed reciprocal effects on growth hormone secretagogue receptor (GHSR) activity, suggesting that the insulinotropic action of the peptide may be directly linked to attenuation of tonic GHSR activity. The fragment was infused in healthy human individuals (n = 10), but no glucoregulatory effect was observed in the chosen dose as compared to placebo. CONCLUSIONS: Small intestinal LEAP2 expression was upregulated after RYGB. The corresponding circulating LEAP238-47 fragment demonstrated strong insulinotropic action in vitro but failed to elicit glucoregulatory effects in healthy human subjects.

OriginalsprogEngelsk
TidsskriftThe Journal of clinical endocrinology and metabolism
Vol/bind106
Udgave nummer2
Sider (fra-til)e966-e981
ISSN0021-972X
DOI
StatusUdgivet - feb. 2021

ID: 61251719